Core Insights - TransMedics Group, Inc. (NASDAQ:TMDX) is gaining attention as a promising investment opportunity among hedge funds due to its strong performance and growth potential [1]. Group 1: Analyst Upgrades - Baird raised its price target on TransMedics from $154 to $168 while maintaining an Outperform rating, following the company's Q4 results that exceeded expectations and a positive 2026 outlook [2]. - Oppenheimer increased its price target from $150 to $175 and kept an Outperform rating, highlighting the company's ongoing investments in clinical advancements, particularly in heart and lung, with kidney being the next focus area [3]. - Piper Sandler raised its price target from $140 to $160 and maintained an Overweight rating, noting that the Q4 results surpassed key financial targets and that the revenue guidance for the year appears solid with potential upside [4]. Group 2: Company Overview - TransMedics Group specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation, aiming to enhance organ quality preservation, assess viability before transplant, and increase donor organ utilization for treating end-stage heart, lung, and liver failure [5].

Average Annual Total Returns Through 12/31/25 (%) QTR1 YTD1 1YR 3YR 5YR 10YR 15YR 20YR 25YR 35YR 45YR Small-Cap 1.95 8.95 8.95 13.90 8.38 11.11 9.20 8.23 9.61 10.84 11.45 Russell 2000 2.19 12.81 12.81 13.73 6.09 9.62 9.47 8.20 8.21 10.25 9.85 Annual Operating Expenses: 0.93 1 Not annualized. Important Performance and Disclosure Information Important Performance and Expense Information All performance information reflects past performance, is presented on a total return basis, reflects the reinve ...

Core Insights - March 2026 presents long-term investors with market pullbacks despite accelerating fundamentals, indicating potential investment opportunities [1] Company Summaries 1. Axon Enterprise - Axon has transformed into an AI-powered public safety platform, moving beyond its original product offerings of TASERs and body cameras [3] - Q4 2025 revenue reached $797 million, a 39% year-over-year increase, with full-year revenue at $2.8 billion, marking four consecutive years of over 30% growth [4] - Annual recurring revenue surpassed $1.3 billion, growing 35%, and future contracted bookings reached $14.4 billion, up 43% [4] - The company targets $6 billion in annual revenue by 2028 with 28% adjusted EBITDA margins, indicating significant growth potential [6] 2. Vertiv - Vertiv supplies power and cooling solutions for data centers, with demand surging due to the AI infrastructure build-out [8] - Full-year 2025 revenue was $10.2 billion, up 28% year-over-year, with adjusted operating margins expanding to 20.4% [9] - Organic orders increased by 81%, and the company ended 2025 with a backlog of $15 billion, equivalent to over a year of revenue [9] - The launch of OneCore integrated modular solutions and a Digital Twin platform positions Vertiv for continued growth in high-density AI data centers [10] 3. TransMedics Group - TransMedics operates the Organ Care System (OCS), revolutionizing organ transport by keeping donor organs warm during transit [12] - Full-year 2025 revenue reached $605.5 million, a 37% increase, with OCS Liver accounting for 36% of U.S. liver transplant procedures [13] - The company performed 5,139 U.S. OCS transplants in 2025, up from 3,735 in 2024, and is expanding into European markets [15] - TransMedics is positioned to dominate the organ logistics market with no viable competitors [16] 4. Fair Isaac - Fair Isaac is a leading credit score company, with its scores used in most mortgage, auto loan, and credit card decisions in the U.S. [17] - Fiscal year 2025 revenue was $1.99 billion, up 15.9%, with a net income of $651.9 million and a net profit margin of 32.8% [18] - The introduction of FICO Score 10T is expected to drive incremental licensing revenue, particularly in the mortgage market [20] - The company has announced a $1.5 billion stock buyback, indicating strong financial health and a favorable entry point for investors [21]

Core Viewpoint - Joby Aviation has experienced a significant decline in its stock price, dropping nearly 25% year-to-date and trading lower than five years ago, raising questions about its valuation and future prospects [1]. Group 1: Company Overview - Joby Aviation designs and manufactures electric vertical takeoff and landing (eVTOL) aircraft, utilizing multiple smaller rotors powered by electric batteries, unlike traditional helicopters [2]. - The flagship model, S-4, is designed to carry four passengers and a pilot for up to 150 miles at a maximum speed of 200 mph, but it is still awaiting FAA safety evaluation before commercial deployment in the U.S. [4]. Group 2: Market Position and Valuation - Joby's current share price is below $10, over 50% lower than its 2025 highs, making it appear attractively priced [5]. - At its peak, Joby was valued at approximately $17.5 billion, comparable to established airlines like Southwest Airlines, yet its current market cap of $9.4 billion exceeds that of American Airlines Group, TransMedics Group, and Lyft [6][8]. Group 3: Business Model and Market Concerns - Joby plans to operate its eVTOL fleet as an air taxi service via an app, similar to Uber, but faces challenges due to its unproven technology and business model being valued higher than established companies in similar sectors [8]. - The potential market for passenger air taxi services is expected to be significantly smaller than that for traditional air travel, emergency medical transport, or ground taxi services [8]. Group 4: Future Outlook - The long-term success of Joby remains uncertain, contingent on FAA certification, production ramp-up, and successful service launches in multiple locations [9]. - The stock is anticipated to be highly volatile, and given its current pricing, many investors may choose to avoid investing in Joby for the time being [9].

Core Viewpoint - TransMedics Group (TMDX) is experiencing strong demand for its organ transplant technology and services, leading to significant stock gains and positioning the company for potential investment opportunities in 2026 [1] Financial Performance - TransMedics reported a fourth-quarter profit of $2.62 per share, a surge of over 1000% from 19 cents per share a year ago, exceeding analysts' expectations of 36 cents per share [1] - Fourth-quarter sales increased by 32% to $161 million, although this was below the analysts' target of $174 million [1] - Earnings have more than doubled in the last three quarters, contributing to the company's profitability over the past two years [1] Market Position - The stock has formed a cup-with-handle base with a buy point of 151.85, indicating a potential breakout opportunity [1] - TransMedics ranks fourth in the medical products group, with a Composite Rating of 96 out of 99 and a Relative Strength Rating of 89, indicating strong performance compared to other stocks [1] - The stock has gained 21% year to date, and mutual funds have been net buyers over the past 13 weeks, resulting in an Accumulation/Distribution Rating of B+ [1] Future Outlook - Analysts predict a 47% decline in earnings growth for 2026, estimating profit to drop to $2.56 per share, but expect a rebound in 2027 with a 45% increase to $3.71 per share [1] - For 2026, TransMedics has provided revenue guidance of $742 million, closely aligning with the FactSet consensus estimate of $737.5 million [1]

Core Viewpoint - The company achieved record performance in Q4 2025, confirming management's belief that Q3 seasonality was temporary and that the U.S. transplant market would recover in the final quarter [1] Market Performance - The U.S. liver, heart, and lung transplant volumes grew by 25% since 2022 with the OCS NOP, whereas they would have declined by 1% without it [1] - OCS Liver now accounts for 36% of the total U.S. liver transplant volume, attributed to clinical leadership and execution excellence [1] Logistics and Operations - The company maintained high logistics efficiency with a fleet of 22 aircraft covering approximately 80% of NOP missions requiring air transport [1] - The company successfully navigated external challenges and competitive disruptions throughout the year, demonstrating the resilience of the OCS NOP integrated service model [1] Financial Performance - A significant income tax benefit of $83.8 million was reported due to the release of a valuation allowance, indicating management's confidence in long-term, sustainable profitability [1]

Core Insights - Glaukos reported a quarterly loss of $0.28 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.22, representing an earnings surprise of -26.47% [1] - The company achieved revenues of $143.12 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 0.13% and showing a year-over-year increase from $105.5 million [2] - The stock has underperformed the market, losing about 3.1% since the beginning of the year compared to the S&P 500's decline of 0.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $131.98 million, and for the current fiscal year, it is -$0.33 on revenues of $610.61 million [7] - The estimate revisions trend for Glaukos was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Instruments industry, to which Glaukos belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, TransMedics, is expected to report quarterly earnings of $0.41 per share, reflecting a year-over-year change of +115.8%, with revenues projected to be $155.91 million, up 28.2% from the previous year [9][10]

分组1 - DexCom reported quarterly earnings of $0.68 per share, exceeding the Zacks Consensus Estimate of $0.65 per share, and showing an increase from $0.45 per share a year ago, representing an earnings surprise of +4.62% [1] - The company achieved revenues of $1.26 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.64% and up from $1.11 billion year-over-year [2] - DexCom has outperformed the market with a 2.7% increase in shares since the beginning of the year, compared to the S&P 500's gain of 1.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.48 on revenues of $1.18 billion, and for the current fiscal year, it is $2.47 on revenues of $5.22 billion [7] - The Medical - Instruments industry, to which DexCom belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

Core Thesis - TransMedics Group, Inc. (TMDX) is positioned favorably in the organ transplantation market with its innovative Organ Care System, which enhances organ viability and expands the transplantable organ pool [2][3]. Company Overview - TransMedics is a U.S.-based medtech company that has shifted from selling hardware to a recurring-revenue model, retaining ownership of its Organ Care System consoles and generating revenue from high-margin consumables and clinical services [2]. - The company has developed a comprehensive approach that includes training and certification for hospital staff, creating significant switching costs and integrating deeply into transplant workflows [3]. Technology and Market Position - The Organ Care System technology is recognized as superior to competitors, with FDA approvals for heart, lung, and liver transplants, and kidney applications anticipated by 2027 [3]. - By extending preservation times and minimizing cold ischemia, TransMedics addresses inefficiencies in organ donation, potentially increasing the overall transplant market [3]. Financial Performance - TransMedics achieved profitability in 2024, with Q3 2025 revenue reported at $144 million and gross margins nearing 60% [4]. - The company holds approximately 19% market share in U.S. heart, lung, and liver transplants, with opportunities for increased penetration and entry into kidney transplants [4]. Growth Potential - Management targets operating margins of 30% and aims for significantly higher transplant volumes, indicating a strong multi-year growth outlook [5]. - Potential international expansion and entry into kidney transplants could further enlarge the addressable market, although challenges exist in Europe due to existing protocols and lower-cost alternatives [4][5]. Stock Performance - TMDX's stock price has increased by approximately 45.04% since previous bullish coverage, driven by improving profitability and adoption momentum [6].

Group 1 - TransMedics Group (TMDX) is highlighted as a focus on the IBD 50 Growth Stocks To Watch list, indicating strong market interest and potential for growth [1] - The company specializes in preserving organs for transplant, achieving utilization rates of at least 96% for organ transplants using its technology, which underscores its effectiveness in the medical technology sector [1] - TransMedics Group has received a Relative Strength Rating upgrade, indicating improved price strength and market performance, with ratings over 90, suggesting strong investor confidence [1] Group 2 - Analysts predict that earnings for TransMedics Group are expected to surge again, indicating positive financial outlook and potential for increased stock value [1] - The company is nearing a buy point, which suggests that it may be an opportune time for investors to consider purchasing shares [1] - The stock has shown improved relative strength, hitting benchmarks above 80, which is a positive indicator for potential investors [1]